ArticleVirus genes2026
Functional contribution of Epstein-Barr virus BARF1 residues 35-39 to viable cell maintenance under serum deprivation and tumor formation.
Article in Virus genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epstein-Barr virus (EBV) BamHI-A rightward frame 1 (BARF1) is a viral oncogene implicated in epithelial malignancies, but the determinants of its transforming activity remain incompletely defined. We generated BARF1 truncation constructs and targeted mutants to examine the contribution of residues 35-38 and adjacent Ser39 in BALB/c 3T3 fibroblasts using serum deprivation, tumorigenicity, BCL-2 expression, and molecular docking assays. Deletion of residues 35-38 in full-length BARF1 reduced viable cell maintenance under severe serum deprivation, whereas Ser39-to-Ala substitution in the BARF1 1-56 background markedly reduced the viable cell advantage of this fragment. Neither mutant produced detectable tumors during the 28-day observation period. Full-length BARF1 induced tumors in all animals, whereas BARF1 1-56 retained partial tumor-forming activity. BARF1 1-46 maintained higher viable cell numbers under serum-limiting conditions but produced no detectable tumors, suggesting a contribution of residues 47-56 to tumor formation. BCL-2 remained detectable in both non-tumor-forming mutants. Exploratory docking predicted a more favorable score and distinct positioning for the wild-type 35-39 peptide relative to the catalytic subunit of cAMP-dependent protein kinase A (PKA) than for the mutant peptides; however, this analysis does not demonstrate Ser39 phosphorylation or PKA-dependent BARF1 activity. Overall, these findings support a functional contribution of the BARF1 region encompassing residues 35-39 to viable cell maintenance under serum deprivation and tumor formation. Because construct-level BARF1 protein abundance, stability, secretion, and localization were not assessed, the observed phenotypes cannot be attributed solely to the altered residues.
Indexed as
Identifiers
42749966What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.